14.04.2014 Views

Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust

Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust

Assessing Vaccine Efficacy and Effectiveness in ... - The INCLEN Trust

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Assess<strong>in</strong>g</strong> <strong>Vacc<strong>in</strong>e</strong> <strong>Efficacy</strong> <strong>and</strong><br />

<strong>Effectiveness</strong> <strong>in</strong> Observational Studies<br />

Steven Black, MD<br />

Professor of Pediatrics<br />

Center for Global Health<br />

University of C<strong>in</strong>c<strong>in</strong>nati Children’s Hospital<br />

C<strong>in</strong>c<strong>in</strong>nati, Ohio USA


Why do we care?<br />

Why are observational assessments of effectiveness useful?<br />

• Cl<strong>in</strong>ical trials may not give a “true” assessment<br />

of the vacc<strong>in</strong>e effect<br />

– Population differences<br />

– Cl<strong>in</strong>ical trial exclusion criteria<br />

– Lack of measurement of some effects that might<br />

not have been anticipated or that can not be<br />

observed <strong>in</strong> a cl<strong>in</strong>ical trial<br />

• Indirect effects


<strong>Efficacy</strong> Versus <strong>Effectiveness</strong><br />

• <strong>Efficacy</strong>: the specific reduction <strong>in</strong> attack rate<br />

between the vacc<strong>in</strong>ated <strong>and</strong> unvacc<strong>in</strong>ated<br />

group <strong>in</strong> a cl<strong>in</strong>ical trial:<br />

ve= (1-Rv/Rp) x 100%<br />

• <strong>Effectiveness</strong>: reduction <strong>in</strong> cl<strong>in</strong>ical events that<br />

might be expected to be associated with the<br />

disease but could also be caused by other<br />

agents.


Observational Studies: <strong>The</strong> Good News<br />

• Observational studies have the advantage of<br />

be<strong>in</strong>g able to assess impact <strong>in</strong> the actual<br />

population of <strong>in</strong>terest.<br />

• Results can be used to evaluate or confirm cost<br />

effectiveness estimates.<br />

• Changes <strong>in</strong> vacc<strong>in</strong>e effect can be tracked over<br />

time.<br />

• Unanticipated outcomes can be assessed.<br />

• Impact of partial or off schedule dos<strong>in</strong>g can be<br />

assessed.


Observational Studies: <strong>The</strong> Bad News<br />

• Observational studies are observational !!<br />

– <strong>The</strong>re is no predef<strong>in</strong>ed control group.<br />

– Non vacc<strong>in</strong>ees tend to be different than vacc<strong>in</strong>ees.<br />

– Historical controls can <strong>in</strong>troduce the risk of<br />

confound<strong>in</strong>g.<br />

• Other non-vacc<strong>in</strong>e secular changes can<br />

dramatically impact assessment<br />

– Cyclic changes <strong>in</strong> serotype distribution unrelated to<br />

vacc<strong>in</strong>e.<br />

– Changes <strong>in</strong> cl<strong>in</strong>ical practice unrelated to vacc<strong>in</strong>e.


QUESTION<br />

Changes <strong>in</strong> disease <strong>in</strong>cidence or serotype<br />

distribution can be impacted by:<br />

a. <strong>Vacc<strong>in</strong>e</strong><br />

b. Antibiotic use<br />

c. Secular trends<br />

d. all of the above<br />

e. Not a, b or c.


Observational Studies to Assess<br />

<strong>Efficacy</strong><br />

Positive Examples


Cases per 100,000<br />

Rates of <strong>in</strong>vasive pneumococcal disease<br />

among children


Cases/100,000 population<br />

Rates of Penicill<strong>in</strong>-Nonsusceptible IPD<br />

by Age Group<br />

ABCs 1998/1999 <strong>and</strong> 2004<br />

80<br />

70<br />

60<br />

50<br />

40<br />

30<br />

20<br />

10<br />

0<br />

1998/9 2004<br />

55% reduction<br />


Rate per 100,000 population<br />

Clos<strong>in</strong>g the Gap<br />

Rates of IPD <strong>in</strong> Australian children


Cases/100,000 population<br />

Example of an Indirect Population Effect<br />

Invasive Pneumococcal Disease<br />

40<br />

35<br />

30<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

1998<br />

1999<br />

Adults 65 years <strong>and</strong> older, 1998-2007<br />

PCV-7<br />

<strong>in</strong>troduced<br />

2000<br />

2001<br />

2002<br />

2003<br />

2004<br />

2005<br />

Nonvacc<strong>in</strong>e<br />

types<br />

PCV-7<br />

types<br />

2006<br />

2007<br />

2007 vs.<br />

basel<strong>in</strong>e<br />

+44%<br />

-92%<br />

basel<strong>in</strong>e<br />

Slide courtesy of Cynthia Whitney, CDC<br />

Year<br />

11


HPA Men<strong>in</strong>gococcal C Surveillance


Resurgence of Hib Disease <strong>in</strong> the UK<br />

BMJ VOLUME 329, 18 SEPTEMBER 2004


Why were these studies successful?<br />

• Invasive disease assessment<br />

– IPD is usually non-dsicretionary. That is, there is<br />

relatively little variation over time <strong>in</strong> the tendency<br />

to seek care.<br />

• Surveillance network was <strong>in</strong> place <strong>and</strong> stable<br />

for years prior to the assessment<br />

– Laboratory <strong>and</strong> case ascerta<strong>in</strong>ment criteria did not<br />

change over time


Observational Studies to Assess<br />

<strong>Efficacy</strong><br />

Precautions


Red Flags for Observational<br />

<strong>Effectiveness</strong> Studies<br />

• Discretionary outcomes: Health care<br />

utilization patterns may change the criteria for<br />

seek<strong>in</strong>g medical care<br />

– New guidel<strong>in</strong>es for otitis media treatment<br />

– Stricter criteria for admission for pneumonia<br />

• Lack of awareness or controll<strong>in</strong>g for other<br />

factors<br />

– Antibiotic usage <strong>and</strong> serotype replacement.


Examples of Possibly Problematic<br />

Observational <strong>Effectiveness</strong> Studies


Examples of Possibly Problematic<br />

Observational <strong>Effectiveness</strong> Studies<br />

Pneumococcal Serotype Replacement


Non-<strong>Vacc<strong>in</strong>e</strong> Serotype Replacement


Secular trends <strong>in</strong> Spa<strong>in</strong><br />

Spa<strong>in</strong>: temporal trends of serotypes<br />

that were (a) <strong>in</strong>cluded <strong>and</strong> (b) the<br />

most prevalent serotypes not <strong>in</strong>cluded<br />

<strong>in</strong> PCV7 among <strong>in</strong>vasive isolates, 1979<br />

to 2007<br />

Some “replacement” stra<strong>in</strong>s were<br />

<strong>in</strong>creas<strong>in</strong>g <strong>in</strong> prevalence years prior to<br />

PCV <strong>in</strong>troduction <strong>in</strong> 2001<br />

Fenoll et al. J Cl<strong>in</strong> Micro 2009; 47: 1012-1020


% of all IPD <strong>in</strong> children < 5 yrs<br />

S<strong>in</strong>gle Clonal Expansion of S. pneumoniae Serotype 19A <strong>in</strong> Korean<br />

Children Before PCV7 Introduction<br />

25<br />

20<br />

23<br />

• All 19A isolates were MDR<br />

• All isolates from 2001 exhibited<br />

Sequence Type (ST) 320<br />

15<br />

10<br />

5<br />

0<br />

0<br />

8<br />

1991-1994 1995-1999 2000-2006<br />

A dramatic <strong>in</strong>crease <strong>in</strong> rates of IPD<br />

caused by antibiotic-resistant<br />

serotype 19A<br />

can occur without vacc<strong>in</strong>ation<br />

Year<br />

Choi et al, 45 th IDSA abstract #202, 2007


Examples of Possibly Problematic<br />

Observational <strong>Effectiveness</strong> Studies<br />

Pneumonia


PCV7 Reduces Pneumonia Admissions<br />

(2004)<br />

65% 73%<br />

39%<br />

30%<br />

17%<br />

26%<br />

41,000 pneumonia admissions<br />

averted among < 2 yo ?????<br />

Grijalva Lancet 2007;369:1179-86.


Hospital Utilization Management<br />

Can Change Rates of Hospitalized Disease


Examples of Possibly Problematic<br />

Observational <strong>Effectiveness</strong> Studies<br />

Otitis Media


Impact of PCV7 on Otitis Media<br />

Grijilva et al Pediatrics Sept 2006


Changes <strong>in</strong> Treatment Guidel<strong>in</strong>es for Otitis Media:<br />

Another Cause of Reduced Medical Visits


Observational <strong>Effectiveness</strong><br />

Studies<br />

A MORE COMPLICATED EXAMPLE:<br />

COMPARATIVE EFFECTIVENESS OF<br />

TWO INFLUENZA VACCINES


Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />

Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly<br />

• Elderly <strong>in</strong>dividuals are relatively unresponsive<br />

to st<strong>and</strong>ard doses of <strong>in</strong>fluenza vacc<strong>in</strong>e<br />

• Elderly <strong>in</strong>dividuals are at higher risk of<br />

complications of <strong>in</strong>fluenza<br />

• Adjuvanted <strong>in</strong>fluenza vacc<strong>in</strong>es are more<br />

immunogenic <strong>in</strong> the elderly<br />

• Study question: Are adjuvanted <strong>in</strong>fluenza<br />

vacc<strong>in</strong>es more effective <strong>in</strong> the prevention of<br />

<strong>in</strong>fluenza?


Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />

Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly<br />

• <strong>The</strong> LIVE study was conducted <strong>in</strong> Italy to compare<br />

MF-59 adjuvanted <strong>in</strong>fluenza vacc<strong>in</strong>e to nonadjuvanted<br />

<strong>in</strong>fluenza vacc<strong>in</strong>e<br />

• Problem: As <strong>in</strong>fluenza vacc<strong>in</strong>e was rout<strong>in</strong>ely<br />

recommended AND adjuvanted vacc<strong>in</strong>e was<br />

preferentially recommended for higher risk<br />

elderly, it was not considered ethical to conduct a<br />

r<strong>and</strong>omized study<br />

• Solution: conduct an observational study <strong>and</strong><br />

adjust for confound<strong>in</strong>g.


Comparative <strong>Effectiveness</strong> of Adjuvanted <strong>and</strong><br />

Unadjuvanted Influenza <strong>Vacc<strong>in</strong>e</strong> <strong>in</strong> the Elderly


Observational <strong>Effectiveness</strong> Studies<br />

• Work best for non-discretionary outcome such as<br />

those requir<strong>in</strong>g hospitalization (sepsis,<br />

men<strong>in</strong>gitis)<br />

• Can assess population effects such as herd<br />

immunity<br />

• Are subject to confound<strong>in</strong>g by secular trends<br />

– Chang<strong>in</strong>g guidel<strong>in</strong>es<br />

– Other factors (antibiotics, cyclic patterns of disease)<br />

• Overall are very useful, but require more<br />

thoughtful <strong>in</strong>terpretation than a RCT.


QUESTION<br />

Which statement is NOT true about observational<br />

studies<br />

a. Provide a real life picture of a vacc<strong>in</strong>e’s effect<br />

b. Monitor chang<strong>in</strong>g effectiveness over time<br />

c. Should only be done if cl<strong>in</strong>ical trials are not<br />

possible<br />

d. Are subject to confound<strong>in</strong>g


Conclusions<br />

• Observational studies offer the opportunity to assess<br />

real life public health impact.<br />

• Observations, both positive <strong>and</strong> negative, are subject<br />

to confound<strong>in</strong>g<br />

– By changes <strong>in</strong> population composition<br />

– By other changes <strong>in</strong> medical care practice<br />

– By temporal trends.<br />

• <strong>The</strong>se studies are none the less <strong>in</strong>dispensible<br />

– Allow ability to assess unanticipated changes <strong>in</strong> vacc<strong>in</strong>e<br />

efficacy or epidemiology<br />

– Can <strong>in</strong>form future vacc<strong>in</strong>e development <strong>and</strong> prioritization

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!